No information is available on the use of nalmefene in nursing mothers. If nalmefene is required by the mother for an opiate overdose, she should withhold nursing until the opiate is out of her system. Because nalmefene has some oral bioavailability, use in a nursing mother might cause abstinence symptoms in a breastfed infant who is opioid tolerant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Nalmefene increases serum prolactin in nonpregnant and nonlactating individuals.[1,2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Kreek MJ, Schluger J, Borg L, et al. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 1999;288:260-9. [PubMed: 9862779]
2.
Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity? Neuropsychopharmacology 2005;30:2254-62. [PubMed: 15988468]
Substance Identification
Substance Name
Nalmefene
CAS Registry Number
55096-26-9
Drug Class
Breast Feeding
Lactation
Milk, Human
Narcotic Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
